Palisade Bio (NASDAQ:PALI) Upgraded to “Hold” at Wall Street Zen

Palisade Bio (NASDAQ:PALI) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other research analysts also recently issued reports on PALI. Clear Str upgraded shares of Palisade Bio to a “strong-buy” rating in a research report on Monday, December 29th. Piper Sandler began coverage on shares of Palisade Bio in a research note on Monday, December 29th. They set an “overweight” rating and a $25.00 price target for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Palisade Bio in a report on Thursday, January 22nd. Stifel Nicolaus initiated coverage on shares of Palisade Bio in a report on Wednesday. They set a “buy” rating and a $5.00 target price for the company. Finally, Citigroup reissued a “buy” rating on shares of Palisade Bio in a research note on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $13.25.

Palisade Bio Stock Performance

NASDAQ PALI opened at $1.77 on Friday. The stock has a market capitalization of $263.73 million, a P/E ratio of -0.83 and a beta of 1.58. Palisade Bio has a 52 week low of $0.53 and a 52 week high of $2.64. The stock has a fifty day moving average of $1.86 and a 200-day moving average of $1.58.

Institutional Trading of Palisade Bio

A number of large investors have recently made changes to their positions in PALI. Perceptive Advisors LLC acquired a new stake in Palisade Bio during the 4th quarter worth $28,318,000. Commodore Capital LP acquired a new stake in shares of Palisade Bio during the fourth quarter worth about $26,896,000. Janus Henderson Group PLC bought a new position in shares of Palisade Bio during the 4th quarter valued at about $24,822,000. RA Capital Management L.P. acquired a new position in shares of Palisade Bio in the 4th quarter valued at approximately $16,742,000. Finally, Eversept Partners LP bought a new stake in Palisade Bio during the 4th quarter worth approximately $12,670,000. Institutional investors own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.